Company Profile
Affimed Stock Price, News & Analysis
Company overview
Business overview
Affimed is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Affimed is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Affimed follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Affimed sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
AFMD is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Affimed is likely to be watched for pipeline progress, conference data, and partnership news over the next three months around oncology.
Investors will also pay attention to clinical readouts, financing and runway, and portfolio progress because platform stories usually reset when the market sees repeatable progress rather than a single one-off update.
If the company adds clearer signals on oncology, the story can move quickly before the next quarter ends.
Recent news
The five most recent feed items are shown below in reverse chronological order.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.